(NASDAQ: LEXX) Lexaria Bioscience's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 19.09%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 27.19%.
Lexaria Bioscience's earnings in 2025 is -$7,319,721.On average, 2 Wall Street analysts forecast LEXX's earnings for 2025 to be -$10,268,267, with the lowest LEXX earnings forecast at -$10,531,556, and the highest LEXX earnings forecast at -$10,004,979. On average, 2 Wall Street analysts forecast LEXX's earnings for 2026 to be -$8,074,193, with the lowest LEXX earnings forecast at -$8,249,719, and the highest LEXX earnings forecast at -$7,898,667.
In 2027, LEXX is forecast to generate -$6,669,986 in earnings, with the lowest earnings forecast at -$6,669,986 and the highest earnings forecast at -$6,669,986.